![Susan F. Langlois](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Historial de carrera de Susan F. Langlois
Antiguos cargos conocidos de Susan F. Langlois.
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
Vasogen, Inc.
![]() Vasogen, Inc. Pharmaceuticals: MajorHealth Technology The Group's principal activities are research and commercialization of therapies designed to target the destructive inflammatory process associated with the development and progression of cardiovascular and neurodegenerative disorders. It's lead product, the Celacade System, is designed to activate the immune response to apoptosis - an important physiological process that regulates inflammation. Celacade has received European regulatory approval under the CE Mark for chronic heart failure and is currently being marketed in Europe by Grupo Ferrer Internacional, S.A. Celacade is also in late-stage development for the treatment of chronic heart failure in the United States. It is also developing a new class of drugs for the treatment of certain neuro-inflammatory disorders. VP025 is the lead drug candidate from this new class. | Consejero General | 01/01/1998 | 23/10/2009 |
Connaught Laboratories Ltd. | Consejero General | 01/01/1972 | 01/01/1992 |
Regulatory Affairs Professionals Society
![]() Regulatory Affairs Professionals Society Miscellaneous Commercial ServicesCommercial Services Regulatory Affairs Professionals Society is a non-profit organization that offers healthcare products. The non-profit company is based in Rockville, MD. | Corporate Officer/Principal | - | - |
Industrial Biotechnology Association of Canada | Corporate Officer/Principal | - | - |
Hemosol Corp. /Old/
![]() Hemosol Corp. /Old/ Pharmaceuticals: MajorHealth Technology Hemosol Inc. is an integrated biopharmaceutical company focused on the development of a portfolio of products based on human hemoglobin. | Director Técnico/Científico/I+D | - | - |
Consejero General | - | - |
Estadísticas
Internacional
Canadá | 5 |
Estados Unidos | 2 |
Operativa
General Counsel | 3 |
Corporate Officer/Principal | 2 |
Chief Tech/Sci/R&D Officer | 1 |
Sectorial
Health Technology | 3 |
Commercial Services | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
Empresas privadas | 5 |
---|---|
Vasogen, Inc.
![]() Vasogen, Inc. Pharmaceuticals: MajorHealth Technology The Group's principal activities are research and commercialization of therapies designed to target the destructive inflammatory process associated with the development and progression of cardiovascular and neurodegenerative disorders. It's lead product, the Celacade System, is designed to activate the immune response to apoptosis - an important physiological process that regulates inflammation. Celacade has received European regulatory approval under the CE Mark for chronic heart failure and is currently being marketed in Europe by Grupo Ferrer Internacional, S.A. Celacade is also in late-stage development for the treatment of chronic heart failure in the United States. It is also developing a new class of drugs for the treatment of certain neuro-inflammatory disorders. VP025 is the lead drug candidate from this new class. | Health Technology |
Hemosol Corp. /Old/
![]() Hemosol Corp. /Old/ Pharmaceuticals: MajorHealth Technology Hemosol Inc. is an integrated biopharmaceutical company focused on the development of a portfolio of products based on human hemoglobin. | Health Technology |
Connaught Laboratories Ltd. | |
Industrial Biotechnology Association of Canada | |
Regulatory Affairs Professionals Society
![]() Regulatory Affairs Professionals Society Miscellaneous Commercial ServicesCommercial Services Regulatory Affairs Professionals Society is a non-profit organization that offers healthcare products. The non-profit company is based in Rockville, MD. | Commercial Services |
- Bolsa de valores
- Insiders
- Susan F. Langlois
- Experiencia